1
|
Lozano V, Etcheverry B, Alabat A, De La Torre S, Fàbregas M, López A, Beato S, Castells M, Vigués F. Robotic assisted vaginoplasty using peritoneal flap and penile skin inversion: Initial experience. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01440-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
2
|
Castells M, Demoly P, Tanno LK. L'anaphylaxie et les vaccins COVID-19. Revue Française d'Allergologie 2021; 61:8S30-8S35. [PMID: 34980951 PMCID: PMC8716577 DOI: 10.1016/s1877-0320(21)00439-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
Les vaccins contre le COVID-19 sont une intervention essentielle pour contrôler la situation pandémique mondiale actuelle. Des réactions anaphylactiques ont été rapidement rapportées après les vaccins à ARN du SARS-CoV2. Ce risque est maintenant mesuré à 2,5-11/1000 000 dans le cadre des programmes de surveillance de la sécurité des vaccins et un seul cas a été documenté comme étant dû au polyéthylène glycol. Les suggestions pour son rôle sont indirectes. La vaccination contre le COVID-19 est en cours de déploiement et les programmes de surveillance sont essentiels pour observer les effets indésirables graves, tels que l'anaphylaxie. Il est important de restaurer la confiance dans la vaccination avec l'ARNm du COVID-19 et d'autres vaccins et les données actuelles confirment leur innocuité sans plus de mortalité que les vaccins précédents. L'anaphylaxie est une condition qui doit être reconnue immédiatement, être traitée par épinéphrine et qui n'est pas limitative et permet la revaccination de certains patients avec prémédication. Il est important de reconnaître les populations à risque telles que les femmes, les patients ayant des antécédents d'allergies et d'anaphylaxie et de reconnaître les rares patients atteints de maladies activant les mastocytes. L'anaphylaxie due au vaccin est extrêmement rare et les cas spécifiques doivent faire l'objet d'une investigation et d'une prise en charge individualisées, soulignant le rôle clé des allergologues dans les programmes de vaccination.
Collapse
Affiliation(s)
- M Castells
- Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts, États-Unis
| | - P Demoly
- Department of Allergy, University Hospital of Montpellier, Montpellier, France
- Institut Desbrest d'épidémiologie et de santé publique, IDESP, University of Montpellier - INSERM, France
- WHO Collaborating Centre on Scientific Classification Support, Montpellier, France
| | - L K Tanno
- Department of Allergy, University Hospital of Montpellier, Montpellier, France
- Institut Desbrest d'épidémiologie et de santé publique, IDESP, University of Montpellier - INSERM, France
- WHO Collaborating Centre on Scientific Classification Support, Montpellier, France
| |
Collapse
|
3
|
Fernández S, Fraga M, Castells M, Colina R, Zunino P. Effect of the administration of Lactobacillus spp. strains on neonatal diarrhoea, immune parameters and pathogen abundance in pre-weaned calves. Benef Microbes 2020; 11:477-488. [PMID: 32877228 DOI: 10.3920/bm2019.0167] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Neonatal calf diarrhoea is one of the challenges faced by intensive farming, and probiotics are considered a promising approach to improve calves' health. The objective of this study was to evaluate the effect of potential probiotic lactobacilli on new-born dairy calves' growth, diarrhoea incidence, faecal score, cytokine expression in blood cells, immunoglobulin A (IgA) levels in plasma and faeces, and pathogen abundance in faeces. Two in vivo assays were conducted at the same farm in two annual calving seasons. Treated calves received one daily dose of the selected lactobacilli (Lactobacillus reuteri TP1.3B or Lactobacillus johnsonii TP1.6) for 10 consecutive days. A faecal score was recorded daily, average daily gain (ADG) was calculated, and blood and faeces samples were collected. Pathogen abundance was analysed by absolute qPCR in faeces using primers directed at Salmonella enterica, rotavirus, coronavirus, Cryptosporidium parvum and three Escherichia coli virulence genes (eae, clpG and Stx1). The faecal score was positively affected by the administration of both lactobacilli strains, and diarrhoea incidence was significantly lower in treated calves. No differences were found regarding ADG, cytokine expression, IgA levels and pathogen abundance. Our findings showed that oral administration of these strains could improve gastrointestinal health, but results could vary depending on the calving season, which may be related to pathogen seasonality and other environmental effects.
Collapse
Affiliation(s)
- S Fernández
- Department of Microbiology, Instituto de Investigaciones Biológicas Clemente Estable, Av Italia 3318, Montevideo, Uruguay
| | - M Fraga
- Animal Health Unit, Instituto Nacional de Investigación Agropecuaria, Ruta 50 Km 11, Colonia, Uruguay
| | - M Castells
- Laboratory of Molecular Virology, Department of Biological Sciences, CENUR Litoral Norte, University of Uruguay, Rivera 1350, 50000 Salto, Uruguay
| | - R Colina
- Laboratory of Molecular Virology, Department of Biological Sciences, CENUR Litoral Norte, University of Uruguay, Rivera 1350, 50000 Salto, Uruguay
| | - P Zunino
- Department of Microbiology, Instituto de Investigaciones Biológicas Clemente Estable, Av Italia 3318, Montevideo, Uruguay
| |
Collapse
|
4
|
Ferastraoaru D, Bax HJ, Bergmann C, Capron M, Castells M, Dombrowicz D, Fiebiger E, Gould HJ, Hartmann K, Jappe U, Jordakieva G, Josephs DH, Levi-Schaffer F, Mahler V, Poli A, Rosenstreich D, Roth-Walter F, Shamji M, Steveling-Klein EH, Turner MC, Untersmayr E, Karagiannis SN, Jensen-Jarolim E. AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer-a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI). Clin Transl Allergy 2020; 10:32. [PMID: 32695309 PMCID: PMC7366896 DOI: 10.1186/s13601-020-00335-w] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2020] [Accepted: 06/11/2020] [Indexed: 12/13/2022] Open
Abstract
Elevated serum IgE levels are associated with allergic disorders, parasitosis and specific immunologic abnormalities. In addition, epidemiological and mechanistic evidence indicates an association between IgE-mediated immune surveillance and protection from tumour growth. Intriguingly, recent studies reveal a correlation between IgE deficiency and increased malignancy risk. This is the first review discussing IgE levels and links to pathological conditions, with special focus on the potential clinical significance of ultra-low serum IgE levels and risk of malignancy. In this Position Paper we discuss: (a) the utility of measuring total IgE levels in the management of allergies, parasitosis, and immunodeficiencies, (b) factors that may influence serum IgE levels, (c) IgE as a marker of different disorders, and d) the relationship between ultra-low IgE levels and malignancy susceptibility. While elevated serum IgE is generally associated with allergic/atopic conditions, very low or absent IgE may hamper anti-tumour surveillance, indicating the importance of a balanced IgE-mediated immune function. Ultra-low IgE may prove to be an unexpected biomarker for cancer risk. Nevertheless, given the early stage of investigations conducted mostly in patients with diseases that influence IgE levels, in-depth mechanistic studies and stratification of malignancy risk based on associated demographic, immunological and clinical co-factors are warranted.
Collapse
Affiliation(s)
- D Ferastraoaru
- Department of Internal Medicine/Allergy and Immunology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY USA
| | - H J Bax
- St. John's Institute of Dermatology, School of Basic & Medical Biosciences, King's College London, Guy's Hospital, 9th Floor, Guy's Tower, London, SE1 9RT UK.,School of Cancer and Pharmaceutical Sciences, King's College London, Guy's Hospital, London, UK
| | - C Bergmann
- ENT Research Institute for Clinical Studies, Essen, Germany
| | - M Capron
- LIRIC-Unite Mixte de Recherche 995 INSERM, Universite de Lille 2, CHRU de Lille, Lille, France
| | - M Castells
- Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA USA
| | - D Dombrowicz
- Recepteurs Nucleaires, Maladies Cardiovasculaires et Diabete, Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, 59000 Lille, France
| | - E Fiebiger
- Division of Gastroenterology, Hepatology and Nutrition Research, Department of Medicine Research, Children's University Hospital Boston, Boston, MA USA
| | - H J Gould
- Randall Centre for Cell and Molecular Biophysics, School of Basic & Medical Biosciences, King's College London, New Hunt's House, London, SE1 1UL UK.,Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK
| | - K Hartmann
- Department of Dermatology, University of Luebeck, Luebeck, Germany
| | - U Jappe
- Interdisciplinary Allergy Outpatient Clinic, Department of Pneumology, University of Luebeck, Luebeck, Germany.,Division of Clinical and Molecular Allergology, Research Center Borstel, Leibniz Lung Center, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Borstel, Germany
| | - G Jordakieva
- Department of Physical Medicine, Rehabilitation and Occupational Medicine, Medical University of Vienna, Vienna, Austria
| | - D H Josephs
- St. John's Institute of Dermatology, School of Basic & Medical Biosciences, King's College London, Guy's Hospital, 9th Floor, Guy's Tower, London, SE1 9RT UK.,School of Cancer and Pharmaceutical Sciences, King's College London, Guy's Hospital, London, UK
| | - F Levi-Schaffer
- Pharmacology and Experimental Therapeutics Unit, The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel
| | - V Mahler
- Division of Allergology, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany
| | - A Poli
- Department of Infection and Immunity, Luxembourg Institute of Health, Esch-Sur-Alzette, Luxembourg
| | - D Rosenstreich
- Department of Internal Medicine/Allergy and Immunology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY USA
| | - F Roth-Walter
- The Interuniversity Messerli Research Inst, Univ. of Vet. Medicine Vienna, Med. Univ. Vienna, Univ. Vienna, Vienna, Austria
| | - M Shamji
- Immunomodulation and Tolerance Group, Imperial College London, and Allergy and Clinical Immunology, Imperial College London, London, UK
| | - E H Steveling-Klein
- Department of Dermatology, Allergy Division, University Hospital Basel, Basel, Switzerland
| | - M C Turner
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.,Universitat Pompeu Fabra (UPF), Barcelona, Spain.,CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,McLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, Canada
| | - E Untersmayr
- Institute of Pathophysiology and Allergy Research, Medical University Vienna, Vienna, Austria
| | - S N Karagiannis
- St. John's Institute of Dermatology, School of Basic & Medical Biosciences, King's College London, Guy's Hospital, 9th Floor, Guy's Tower, London, SE1 9RT UK.,NIHR Biomedical Research Centre at Guy's and St. Thomas' Hospitals and King's College London, Guy's Hospital, King's College London, London, UK
| | - E Jensen-Jarolim
- The Interuniversity Messerli Research Inst, Univ. of Vet. Medicine Vienna, Med. Univ. Vienna, Univ. Vienna, Vienna, Austria.,Institute of Pathophysiology and Allergy Research, Medical University Vienna, Vienna, Austria
| |
Collapse
|
5
|
Garcia-Rodriguez J, Fernandez-Gomez J, Cozar J, Miñana B, Gomez-Veiga F, Rodriguez-Antolin A, Pórtela P, Blanco E, González J, Baena V, Morales P, Villavicencio H, Palou J, Loizaga A, Ciudin A, Mihai D, Martínez Jabaloyas J, Castelló A, Díez N, Romero F, Subirá J, Chávez A, Capapé V, Mata M, Elizalde J, Lobato J, Jiménez J, Pérez Llorca L, Tenza J, Herranz F, Husillos A, López E, Ramírez D, Blaha I, Izquierdo E, Reina L, Passas J, Díez L, Hevia M, Castells M, Concepción Masip T, Plata A, Asuar Aydillo S, Alonso J, Mateos J, Carballido J, Martínez C, Areche J, Rodríguez R, Hevia V, Álvarez S, Requena M, Prieto R, Carazo J, Márquez J, Gómez E, García J, Amón J, Cepeda M, Álvarez L, Rodríguez V, de la Cruz B, Rivero A, Sánchez J, Mainez J, Medina R, Conde M, Castiñeiras J, González Baena A, Sánchez E, Campanario R, Saiz R, Romero E, Morote J, Raventós C, Celma A, Vázquez F, Gómez A, Buendía E, García N. Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry. Actas Urol Esp 2020; 44:156-163. [PMID: 32113829 DOI: 10.1016/j.acuro.2019.06.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2018] [Revised: 03/26/2019] [Accepted: 06/09/2019] [Indexed: 10/24/2022]
Abstract
BACKGROUND The effect of primary androgen deprivation therapy (ADT) in patients with localized prostate cancer (PCa) has not been well documented. The objective of the present study was to analyze the outcome of tumors treated with ADT as primary therapy in the Spanish Prostate Cancer Registry (19.4% of the series). PATIENTS AND METHODS Patients were classified in three groups: 1) with low/intermediate risk clinically localized tumors; 2) with high risk and locally advanced (T3-4) tumors; 3) with metastatic tumors. Time to castration resistance and overall cancer-specific survival were analyzed. In non-metastatic tumors, survivals in patients treated with ADT were compared with data from patients who underwent local treatments from the Spanish Prostate Cancer Registry. RESULTS 703 cases were analyzed. There were significant differences in the time to castration resistance, which was lower in the group of metastatic tumors. During follow-up, there were 179 deaths (25.5%) of which 89 (12.6%) were due to PCa. After 3 years of ADT, only 14.6% of patients in group 1 had died (1% due to PCa), 20.5% in group 2 and 46.8% in group 3 (9.2% and 31.3% due to PCa, respectively). Cancer-specific survival was significantly worse in group 1 using ADT than radical prostatectomy or radiotherapy. In high-risk and locally advanced tumors, ADT also had a lower cancer-specific survival than local treatments. CONCLUSION A longer time until the castration resistance was observed in patients with well- and intermediate-risk localized tumors treated with ADT. Patients with metastatic tumors showed the shortest time to castration resistance.
Collapse
|
6
|
Gamazo P, Victoria M, Schijven JF, Alvareda E, Tort LFL, Ramos J, Lizasoain LA, Sapriza G, Castells M, Bessone L, Colina R. Modeling the Transport of Human Rotavirus and Norovirus in Standardized and in Natural Soil Matrix-Water Systems. Food Environ Virol 2020; 12:58-67. [PMID: 31721078 DOI: 10.1007/s12560-019-09414-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/26/2019] [Accepted: 10/31/2019] [Indexed: 05/24/2023]
Abstract
We modeled Group A Rotavirus (RVA) and Norovirus genogroup II (GII NoV) transport experiments in standardized (crystal quartz sand and deionized water with adjusted pH and ionic strength) and natural soil matrix-water systems (MWS). On the one hand, in the standardized MWS, Rotavirus and Norovirus showed very similar breakthrough curves (BTCs), showing a removal rate of 2 and 1.7 log10, respectively. From the numerical modeling of the experiment, transport parameters of the same order of magnitude were obtained for both viruses. On the other hand, in the natural MWS, the two viruses show very different BTCs. The Norovirus transport model showed significant changes; BTC showed a removal rate of 4 log10, while Rotavirus showed a removal rate of 2.6 log10 similar to the 2 log10 observed on the standardized MWS. One possible explanation for this differential behavior is the difference in the isoelectric point value of these two viruses and the increase of the ionic strength on the natural MWS.
Collapse
Affiliation(s)
- P Gamazo
- Departamento del Agua (Water Department), CENUR LN (North Littoral Regional University Center), Universidad de la República, Gral. Rivera 1350, CP: 50.000, Salto, Uruguay.
| | - M Victoria
- Laboratorio de Virología Molecular, (Molecular Virology Laboratory), CENUR LN (North Littoral Regional University Center), Universidad de la República, Gral. Rivera 1350, CP: 50.000, Salto, Uruguay
| | - J F Schijven
- Department of Earth Sciences, Utrecht University, Budapestlaan 4, P.O. Box 80021, 3508 TA, Utrecht, The Netherlands
- Department of Statistics, Informatics and Modelling, National Institute of Public Health and the Environment (RIVM), P.O. Box 1, 3720, BA, Bilthoven, The Netherlands
| | - E Alvareda
- Departamento del Agua (Water Department), CENUR LN (North Littoral Regional University Center), Universidad de la República, Gral. Rivera 1350, CP: 50.000, Salto, Uruguay
| | - L F L Tort
- Laboratorio de Virología Molecular, (Molecular Virology Laboratory), CENUR LN (North Littoral Regional University Center), Universidad de la República, Gral. Rivera 1350, CP: 50.000, Salto, Uruguay
| | - J Ramos
- Departamento del Agua (Water Department), CENUR LN (North Littoral Regional University Center), Universidad de la República, Gral. Rivera 1350, CP: 50.000, Salto, Uruguay
| | - L A Lizasoain
- Laboratorio de Virología Molecular, (Molecular Virology Laboratory), CENUR LN (North Littoral Regional University Center), Universidad de la República, Gral. Rivera 1350, CP: 50.000, Salto, Uruguay
| | - G Sapriza
- Departamento del Agua (Water Department), CENUR LN (North Littoral Regional University Center), Universidad de la República, Gral. Rivera 1350, CP: 50.000, Salto, Uruguay
| | - M Castells
- Laboratorio de Virología Molecular, (Molecular Virology Laboratory), CENUR LN (North Littoral Regional University Center), Universidad de la República, Gral. Rivera 1350, CP: 50.000, Salto, Uruguay
| | - L Bessone
- Departamento del Agua (Water Department), CENUR LN (North Littoral Regional University Center), Universidad de la República, Gral. Rivera 1350, CP: 50.000, Salto, Uruguay
| | - R Colina
- Laboratorio de Virología Molecular, (Molecular Virology Laboratory), CENUR LN (North Littoral Regional University Center), Universidad de la República, Gral. Rivera 1350, CP: 50.000, Salto, Uruguay
| |
Collapse
|
7
|
Joseph M, Szafron V, Yang B, Srivaths L, Anvari S, Castells M, Noroski L. M030 FERRIC CARBOXYMALTOSE DESENSITIZATION IN REFRACTORY IDIOPATHIC IRON-DEFICIENCY ANEMIA, IRON-INFUSION ANAPHYLAXIS, SEVERE ATOPY AND HYPERTRYPTASEMIA. Ann Allergy Asthma Immunol 2019. [DOI: 10.1016/j.anai.2019.08.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
8
|
Sureda A, Fumadó L, Ferrer M, Garín O, Bonet X, Castells M, Mir MC, Abascal JM, Vigués F, Cecchini L, Suárez JF. Health-related quality of life in men with prostate cancer undergoing active surveillance versus radical prostatectomy, external-beam radiotherapy, prostate brachytherapy and reference population: a cross-sectional study. Health Qual Life Outcomes 2019; 17:11. [PMID: 30642340 PMCID: PMC6332524 DOI: 10.1186/s12955-019-1082-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2018] [Accepted: 01/07/2019] [Indexed: 01/22/2023] Open
Abstract
Background The purpose of this study is to describe Health-Related Quality of Life (HRQoL) of localized prostate cancer patients in an Active Surveillance (AS) program, and to compare them with those undergoing radical prostatectomy (RP), external-beam radiotherapy (XRT) and brachytherapy (BT). Methods Multi-institutional pooled cross-sectional analysis on patients in an AS protocol: < 75 years old; pathologically confirmed LPC (maximum of three positive cylinders); Gleason score < 3 + 4; clinical stage T1a-T2b; and PSA < 15 ng/ml. Exclusion criteria for this study were: less than 6 months in AS, termination of AS protocol, or incomplete data. Patients in AS were matched with those treated with RP, XRT or BT from the ‘Spanish Multicentric Study of Clinically Localized Prostate Cancer’ cohort according to risk group, time from treatment selection to HRQoL survey, and age. Prostate-specific (EPIC) and generic (SF-36) HRQoL instruments were completed. Analysis was stratified by HRQoL survey moment (>or < 2.5 years from treatment selection), and age (>or < 70 years old). Results Median of time from treatment selection to HRQoL survey in the total 396 patients (99 per treatment group) was 2.4 years (range 0.5–8.3). Patients in AS presented higher (better) urinary incontinence scores than RP ones in both stratus of time from treatment selection to HRQoL survey (92.6 vs 67.0 and 81.4 vs 64.4, p < 0.01). Patients in AS for < 2.5 years presented greater sexual scores than any active treatment (p < 0.01), but only statistically higher than RP for those in AS for longer than 2.5 years. The magnitude of the differences between AS and RP groups in both EPIC domains ranged from moderate (0.7 SD) to large (1.0 SD). Regardless of treatment applied, patients presented similar and slightly increased SF-36 scores than US general population reference norms. Nonetheless, patients in AS for < 2.5 years reported worse outcomes than other treatment groups on physical health domains, especially in bodily pain (0.5–0.6 SD), and vitality (0.6–0.8 SD). Conclusions Considering patients’ well-being, AS can be a good therapeutic option due to the low impact caused on urinary continence and sexual function. However, longitudinal studies are required to take into account HRQoL evolution over time. Electronic supplementary material The online version of this article (10.1186/s12955-019-1082-4) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- A Sureda
- Urology Department, Hospital del Mar-IMIM, Autonomous University of Barcelona, Passeig Marítim 25-29, 08003, Barcelona, Spain.,Autonomous University of Barcelona, Barcelona, Spain
| | - L Fumadó
- Urology Department, Hospital del Mar-IMIM, Autonomous University of Barcelona, Passeig Marítim 25-29, 08003, Barcelona, Spain.
| | - M Ferrer
- Autonomous University of Barcelona, Barcelona, Spain.,IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, Spain.,CIBER en Epidemiología y Salud Pública, CIBERESP, Barcelona, Spain
| | - O Garín
- IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, Spain.,CIBER en Epidemiología y Salud Pública, CIBERESP, Barcelona, Spain.,Universitat Pompeu Fabra, Barcelona, Spain
| | - X Bonet
- Hospital Universitari de Bellvitge, l'Hospitalet de Llobregat, Barcelona, Spain
| | - M Castells
- Hospital Universitari de Bellvitge, l'Hospitalet de Llobregat, Barcelona, Spain
| | - M C Mir
- Urology Department, Hospital del Mar-IMIM, Autonomous University of Barcelona, Passeig Marítim 25-29, 08003, Barcelona, Spain
| | - J M Abascal
- Urology Department, Hospital del Mar-IMIM, Autonomous University of Barcelona, Passeig Marítim 25-29, 08003, Barcelona, Spain
| | - F Vigués
- Hospital Universitari de Bellvitge, l'Hospitalet de Llobregat, Barcelona, Spain
| | - L Cecchini
- Urology Department, Hospital del Mar-IMIM, Autonomous University of Barcelona, Passeig Marítim 25-29, 08003, Barcelona, Spain
| | - J F Suárez
- Hospital Universitari de Bellvitge, l'Hospitalet de Llobregat, Barcelona, Spain
| |
Collapse
|
9
|
Gamazo P, Victoria M, Schijven JF, Alvareda E, Tort LFL, Ramos J, Burutaran L, Olivera M, Lizasoain A, Sapriza G, Castells M, Colina R. Evaluation of Bacterial Contamination as an Indicator of Viral Contamination in a Sedimentary Aquifer in Uruguay. Food Environ Virol 2018; 10:305-315. [PMID: 29564721 DOI: 10.1007/s12560-018-9341-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/09/2017] [Accepted: 12/22/2017] [Indexed: 06/08/2023]
Abstract
In Uruguay, groundwater is frequently used for agricultural activities, as well as for human consumption in urban and rural areas. As in many countries worldwide, drinking water microbiological quality is evaluated only according to bacteriological standards and virological analyses are not mentioned in the legislation. In this work, the incidence of human viral (Rotavirus A, Norovirus GII, and human Adenovirus) and bacterial (total and thermotolerant coliform and Pseudomonas aeruginosa) contamination in groundwater in the Salto district, Uruguay, as well as the possible correlation between these groups of microorganisms, was studied. From a total of 134 groundwater samples, 42 (32.1%) were positive for Rotavirus, only 1 (0.7%) for both Rotavirus and Adenovirus, and 96 (72.6%) samples were positive for bacterial indicators. Results also show that Rotavirus presence was not associated with changes in chemical composition of the aquifer water. Bacteriological indicators were not adequate to predict the presence of viruses in individual groundwater samples (well scale), but a deeper spatial-temporal analysis showed that they are promising candidates to assess the viral contamination degree at aquifer scale, since from the number of wells with bacterial contamination the number of wells with viral contamination could be estimated.
Collapse
Affiliation(s)
- P Gamazo
- Departamento del Agua (Water Department), CENUR LN (North Littoral Regional University Center), Universidad de la República, Gral. Rivera 1350, Salto, CP: 50.000, Uruguay
| | - M Victoria
- Laboratorio de Virología Molecular, (Molecular Virology Laboratory), CENUR LN (North Littoral Regional University Center), Universidad de la República, Gral. Rivera 1350, Salto, CP: 50.000, Uruguay
| | - J F Schijven
- Department of Earth Sciences, Utrecht University, Budapestlaan 4, P.O. Box 80021, 3508 TA, Utrecht, The Netherlands
- Department of Statistics, Informatics and Modelling, National Institute of Public Health and the Environment (RIVM), P.O. Box 1, 3720 BA, Bilthoven, The Netherlands
| | - E Alvareda
- Departamento del Agua (Water Department), CENUR LN (North Littoral Regional University Center), Universidad de la República, Gral. Rivera 1350, Salto, CP: 50.000, Uruguay
| | - L F L Tort
- Laboratorio de Virología Molecular, (Molecular Virology Laboratory), CENUR LN (North Littoral Regional University Center), Universidad de la República, Gral. Rivera 1350, Salto, CP: 50.000, Uruguay
| | - J Ramos
- Departamento del Agua (Water Department), CENUR LN (North Littoral Regional University Center), Universidad de la República, Gral. Rivera 1350, Salto, CP: 50.000, Uruguay
| | - L Burutaran
- Laboratorio de Virología Molecular, (Molecular Virology Laboratory), CENUR LN (North Littoral Regional University Center), Universidad de la República, Gral. Rivera 1350, Salto, CP: 50.000, Uruguay
| | - M Olivera
- Departamento del Agua (Water Department), CENUR LN (North Littoral Regional University Center), Universidad de la República, Gral. Rivera 1350, Salto, CP: 50.000, Uruguay
| | - A Lizasoain
- Laboratorio de Virología Molecular, (Molecular Virology Laboratory), CENUR LN (North Littoral Regional University Center), Universidad de la República, Gral. Rivera 1350, Salto, CP: 50.000, Uruguay
| | - G Sapriza
- Departamento del Agua (Water Department), CENUR LN (North Littoral Regional University Center), Universidad de la República, Gral. Rivera 1350, Salto, CP: 50.000, Uruguay
| | - M Castells
- Laboratorio de Virología Molecular, (Molecular Virology Laboratory), CENUR LN (North Littoral Regional University Center), Universidad de la República, Gral. Rivera 1350, Salto, CP: 50.000, Uruguay
| | - R Colina
- Laboratorio de Virología Molecular, (Molecular Virology Laboratory), CENUR LN (North Littoral Regional University Center), Universidad de la República, Gral. Rivera 1350, Salto, CP: 50.000, Uruguay.
| |
Collapse
|
10
|
Tanno LK, Torres MJ, Castells M, Demoly P. What can we learn in drug allergy management from World Health Organization's international classifications? Allergy 2018; 73:987-992. [PMID: 29105793 DOI: 10.1111/all.13335] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/15/2017] [Indexed: 12/13/2022]
Abstract
Drug hypersensitivity reactions (DHRs) represent growing health problem worldwide, affecting more than 7% of the general population, and represent an important public health problem. However, knowledge in DHRs morbidity and mortality epidemiological data is still not optimal and international comparable standards remain poorly accessed. Institutional databases worldwide increasingly use the WHO International Classification of Diseases (ICD) system to classify diagnoses, health services utilization, and death data. The misclassification of disorders in the ICD system contributes to a lack of ascertainment and recognition of their importance for healthcare planning and resource allocation. It also hampers clinical practice and prevention actions. To further inform the allergy community and to ensure that the revision process is transparent as advised in the WHO ICD-11 revision agenda, we report the advances and use of the pioneering "Drug hypersensitivity" subsection of ICD-11 and implementation in the WHO International Classification of Health Interventions (ICHI). The new classification addressed to DHRs will enable the collection of more accurate epidemiological data to support quality management of patients with drug allergies and better facilitate healthcare planning and decision-making and public health measures to prevent and reduce the morbidity and mortality attributable to DHRs.
Collapse
Affiliation(s)
- L. K. Tanno
- Hospital Sírio Libanês; São Paulo Brazil
- University Hospital of Montpellier; Montpellier France
- UMR-S 1136, IPLESP, Equipe EPAR; Sorbonne Universités; UPMC Paris 06; Paris France
| | - M. J. Torres
- Allergy Unit; IBIMA-Regional University Hospital of Malaga, UMA; Malaga Spain
| | - M. Castells
- Division of Rheumatology, Immunology and Allergy; Department of Medicine; Brigham and Women's Hospital; Harvard Medical School; Boston MA USA
| | - P. Demoly
- University Hospital of Montpellier; Montpellier France
- UMR-S 1136, IPLESP, Equipe EPAR; Sorbonne Universités; UPMC Paris 06; Paris France
| | | |
Collapse
|
11
|
Castells M, Schild C, Caffarena D, Bok M, Giannitti F, Armendano J, Riet-Correa F, Victoria M, Parreño V, Colina R. Prevalence and viability of group A rotavirus in dairy farm water sources. J Appl Microbiol 2018; 124:922-929. [PMID: 29316065 DOI: 10.1111/jam.13691] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2017] [Revised: 12/30/2017] [Accepted: 01/02/2018] [Indexed: 12/27/2022]
Abstract
AIM To analyse group A rotavirus (RVA) environmental contamination in waters used for calves' consumption and to assess viral viability in dairy farm water sources. METHODS AND RESULTS We analysed 202 samples of water used for calves' consumption and RVA was detected by RT-qPCR in 35·1% (95% CI: 28·9-42·0%). A marked pattern of seasonality was observed with higher frequency of detection in colder than warmer months (P = 0·002). There was no association between viral load and season or between the number of milking cows in the herd and the detection of RVA in the farm. The viability of the RVA particles detected was confirmed by isolation of RVA in cell culture from 5 of 10 water samples. Furthermore, an RVA waterborne outbreak of neonatal calf diarrhoea was described. CONCLUSIONS We demonstrate that RVA is frequent in dairy farm waters, and that the virus is infectious and capable of generating a diarrhoea outbreak. SIGNIFICANCE AND IMPACT OF THE STUDY Neonatal diarrhoea syndrome leads to economic losses to the livestock industry worldwide. To determine transmission routes is essential to take action in this regard and reduce the impact that this syndrome has for the livestock production. The results obtained in this work alert the dairy industry and highlight that mitigation strategies are crucial to improve the microbiological quality of this water.
Collapse
Affiliation(s)
- M Castells
- Laboratorio de Virología Molecular, CENUR Litoral Norte, Centro Universitario de Salto, Universidad de la República, Salto, Uruguay
| | - C Schild
- Plataforma de Investigación en Salud Animal, Instituto Nacional de Investigación Agropecuaria (INIA), La Estanzuela, Colonia, Uruguay
| | - D Caffarena
- Plataforma de Investigación en Salud Animal, Instituto Nacional de Investigación Agropecuaria (INIA), La Estanzuela, Colonia, Uruguay
| | - M Bok
- Sección de Virus Gastroentéricos, Instituto de Virología, CICV y A, INTA Castelar, Buenos Aires, Argentina
| | - F Giannitti
- Plataforma de Investigación en Salud Animal, Instituto Nacional de Investigación Agropecuaria (INIA), La Estanzuela, Colonia, Uruguay.,Veterinary Population Medicine Department, College of Veterinary Medicine, University of Minnesota, Saint Paul, MN, USA
| | - J Armendano
- Facultad de Ciencias Agrarias, Universidad Nacional de Mar del Plata, Balcarce, Buenos Aires, Argentina
| | - F Riet-Correa
- Plataforma de Investigación en Salud Animal, Instituto Nacional de Investigación Agropecuaria (INIA), La Estanzuela, Colonia, Uruguay
| | - M Victoria
- Laboratorio de Virología Molecular, CENUR Litoral Norte, Centro Universitario de Salto, Universidad de la República, Salto, Uruguay
| | - V Parreño
- Sección de Virus Gastroentéricos, Instituto de Virología, CICV y A, INTA Castelar, Buenos Aires, Argentina
| | - R Colina
- Laboratorio de Virología Molecular, CENUR Litoral Norte, Centro Universitario de Salto, Universidad de la República, Salto, Uruguay
| |
Collapse
|
12
|
Ferrer F, Pont A, De Blas R, Boladeras A, Garin O, Ventura M, Garcia E, Gutierrez C, Zardoya E, Rojas F, Bavestrello P, Laplana M, Mases J, Castells M, Guix I, Suarez J, Picon C, Pera J, Ferrer M, Guedea F. Toxicity and Quality of Life (QoL) Comparison between Two Escalation Dose Fractionation Protocols With Steroatactic Body Radiation Therapy in Prostate Cancer. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
13
|
Climent Duran M, Mellado B, Piulats Rodriguez J, Heras Lopez L, Juan M, Sáez M, Reig O, Montesa A, Suarez J, Hajianfar R, Ribal M, Rubio J, Castells M, Villatoro R, Sandiego S, Olmos Hidalgo D. Longer time from diagnosis to docetaxel treatment results in a shorter survival in metastatic hormonosensitive prostate cancer (mHSPC) patients treated with chemotherapy+androgen deprivation therapy (ADT). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx370.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
14
|
Muraro A, Lemanske RF, Castells M, Torres MJ, Khan D, Simon HU, Bindslev-Jensen C, Burks W, Poulsen LK, Sampson HA, Worm M, Nadeau KC. Precision medicine in allergic disease-food allergy, drug allergy, and anaphylaxis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. Allergy 2017; 72:1006-1021. [PMID: 28122115 DOI: 10.1111/all.13132] [Citation(s) in RCA: 113] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/22/2017] [Indexed: 12/30/2022]
Abstract
This consensus document summarizes the current knowledge on the potential for precision medicine in food allergy, drug allergy, and anaphylaxis under the auspices of the PRACTALL collaboration platform. PRACTALL is a joint effort of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology, which aims to synchronize the European and American approaches to allergy care. Precision medicine is an emerging approach for disease treatment based on disease endotypes, which are phenotypic subclasses associated with specific mechanisms underlying the disease. Although significant progress has been made in defining endotypes for asthma, definitions of endotypes for food and drug allergy or for anaphylaxis lag behind. Progress has been made in discovery of biomarkers to guide a precision medicine approach to treatment of food and drug allergy, but further validation and quantification of these biomarkers are needed to allow their translation into practice in the clinical management of allergic disease.
Collapse
Affiliation(s)
- A. Muraro
- Food Allergy Referral Centre Veneto Region; Department of Women and Child Health; Padua General University Hospital; Padua Italy
| | - R. F. Lemanske
- Department of Pediatrics; University of Wisconsin School of Medicine and Public Health; Madison WI USA
| | - M. Castells
- Drug Hypersensitivity and Desensitization Center; Brigham & Women's Hospital; Harvard Medical School; Boston MA USA
| | - M. J. Torres
- Allergy Unit; Regional University Hospital of Malaga-IBIMA; UMA; Malaga Spain
| | - D. Khan
- Division of Allergy & Immunology; Department of Internal Medicine; University of Texas Southwestern Medical Center; Dallas TX USA
| | - H.-U. Simon
- Institute of Pharmacology; University of Bern; Bern Switzerland
| | - C. Bindslev-Jensen
- Department of Dermatology and Allergy Centre; Odense Research Center for Anaphylaxis (ORCA); Odense University Hospital; Odense Denmark
| | - W. Burks
- Department of Pediatrics; University of North Carolina; Chapel Hill NC USA
| | - L. K. Poulsen
- Allergy Clinic; Copenhagen University Hospital at Gentofte Hospital; Copenhagen Denmark
| | - H. A. Sampson
- Icahn School of Medicine at Mount Sinai; New York NY USA
| | - M. Worm
- Klinik für Dermatologie; Charité - Universitätsmedizin Berlin; Berlin Germany
| | - K. C. Nadeau
- Department of Medicine; Stanford University School of Medicine; Stanford CA USA
- Sean N. Parker Center for Allergy and Asthma Research; Stanford University School of Medicine; Stanford CA USA
| |
Collapse
|
15
|
Jensen‐Jarolim E, Bax HJ, Bianchini R, Capron M, Corrigan C, Castells M, Dombrowicz D, Daniels‐Wells TR, Fazekas J, Fiebiger E, Gatault S, Gould HJ, Janda J, Josephs DH, Karagiannis P, Levi‐Schaffer F, Meshcheryakova A, Mechtcheriakova D, Mekori Y, Mungenast F, Nigro EA, Penichet ML, Redegeld F, Saul L, Singer J, Spicer JF, Siccardi AG, Spillner E, Turner MC, Untersmayr E, Vangelista L, Karagiannis SN. AllergoOncology - the impact of allergy in oncology: EAACI position paper. Allergy 2017; 72:866-887. [PMID: 28032353 PMCID: PMC5498751 DOI: 10.1111/all.13119] [Citation(s) in RCA: 63] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/23/2016] [Indexed: 12/19/2022]
Abstract
Th2 immunity and allergic immune surveillance play critical roles in host responses to pathogens, parasites and allergens. Numerous studies have reported significant links between Th2 responses and cancer, including insights into the functions of IgE antibodies and associated effector cells in both antitumour immune surveillance and therapy. The interdisciplinary field of AllergoOncology was given Task Force status by the European Academy of Allergy and Clinical Immunology in 2014. Affiliated expert groups focus on the interface between allergic responses and cancer, applied to immune surveillance, immunomodulation and the functions of IgE-mediated immune responses against cancer, to derive novel insights into more effective treatments. Coincident with rapid expansion in clinical application of cancer immunotherapies, here we review the current state-of-the-art and future translational opportunities, as well as challenges in this relatively new field. Recent developments include improved understanding of Th2 antibodies, intratumoral innate allergy effector cells and mediators, IgE-mediated tumour antigen cross-presentation by dendritic cells, as well as immunotherapeutic strategies such as vaccines and recombinant antibodies, and finally, the management of allergy in daily clinical oncology. Shedding light on the crosstalk between allergic response and cancer is paving the way for new avenues of treatment.
Collapse
Affiliation(s)
- E. Jensen‐Jarolim
- The Interuniversity Messerli Research InstituteUniversity of Veterinary Medicine ViennaMedical University of ViennaViennaAustria
- Institute of Pathophysiology & Allergy ResearchCenter of Pathophysiology, Infectiology & ImmunologyMedical University ViennaViennaAustria
| | - H. J. Bax
- Division of Genetics & Molecular MedicineFaculty of Life Sciences and MedicineSt. John's Institute of DermatologyKing's College LondonLondonUK
- Division of Cancer StudiesFaculty of Life Sciences & MedicineKing's College LondonGuy's HospitalLondonUK
| | - R. Bianchini
- The Interuniversity Messerli Research InstituteUniversity of Veterinary Medicine ViennaMedical University of ViennaViennaAustria
| | - M. Capron
- LIRIC‐Unité Mixte de Recherche 995 INSERMUniversité de Lille 2CHRU de LilleLilleFrance
| | - C. Corrigan
- Division of Asthma, Allergy and Lung BiologyMedical Research Council and Asthma UK Centre in Allergic Mechanisms in AsthmaKing's College LondonLondonUK
| | - M. Castells
- Division of Rheumatology, Immunology and AllergyDepartment of MedicineBrigham and Women's HospitalHarvard Medical SchoolBostonMAUSA
| | - D. Dombrowicz
- INSERMCHU LilleEuropean Genomic Institute of DiabetesInstitut Pasteur de LilleU1011 – récepteurs nucléaires, maladies cardiovasculaires et diabèteUniversité de LilleLilleFrance
| | - T. R. Daniels‐Wells
- Division of Surgical OncologyDepartment of SurgeryDavid Geffen School of Medicine at UCLALos AngelesCAUSA
| | - J. Fazekas
- The Interuniversity Messerli Research InstituteUniversity of Veterinary Medicine ViennaMedical University of ViennaViennaAustria
- Institute of Pathophysiology & Allergy ResearchCenter of Pathophysiology, Infectiology & ImmunologyMedical University ViennaViennaAustria
| | - E. Fiebiger
- Division of Gastroenterology, Hepatology and Nutrition ResearchDepartment of Medicine ResearchChildren's University Hospital BostonBostonMAUSA
| | - S. Gatault
- LIRIC‐Unité Mixte de Recherche 995 INSERMUniversité de Lille 2CHRU de LilleLilleFrance
| | - H. J. Gould
- Division of Asthma, Allergy and Lung BiologyMedical Research Council and Asthma UK Centre in Allergic Mechanisms in AsthmaKing's College LondonLondonUK
- Randall Division of Cell and Molecular BiophysicsKing's College LondonLondonUK
- NIHR Biomedical Research Centre at Guy's and St. Thomas’ Hospitals and King's College LondonKing's College LondonGuy's HospitalLondonUK
| | - J. Janda
- Center PigmodInstitute of Animal Physiology and GeneticsAcademy of Sciences of Czech RepublicLibechovCzech Republic
| | - D. H. Josephs
- Division of Genetics & Molecular MedicineFaculty of Life Sciences and MedicineSt. John's Institute of DermatologyKing's College LondonLondonUK
- Division of Cancer StudiesFaculty of Life Sciences & MedicineKing's College LondonGuy's HospitalLondonUK
| | - P. Karagiannis
- Division of Genetics & Molecular MedicineFaculty of Life Sciences and MedicineSt. John's Institute of DermatologyKing's College LondonLondonUK
- NIHR Biomedical Research Centre at Guy's and St. Thomas’ Hospitals and King's College LondonKing's College LondonGuy's HospitalLondonUK
| | - F. Levi‐Schaffer
- Pharmacology and Experimental Therapeutics UnitFaculty of MedicineSchool of PharmacyThe Institute for Drug ResearchThe Hebrew University of JerusalemJerusalemIsrael
| | - A. Meshcheryakova
- Institute of Pathophysiology & Allergy ResearchCenter of Pathophysiology, Infectiology & ImmunologyMedical University ViennaViennaAustria
| | - D. Mechtcheriakova
- Institute of Pathophysiology & Allergy ResearchCenter of Pathophysiology, Infectiology & ImmunologyMedical University ViennaViennaAustria
| | - Y. Mekori
- Sackler Faculty of MedicineTel‐Aviv UniversityTel‐AvivIsrael
| | - F. Mungenast
- Institute of Pathophysiology & Allergy ResearchCenter of Pathophysiology, Infectiology & ImmunologyMedical University ViennaViennaAustria
| | - E. A. Nigro
- IRCCS San Raffaele Scientific InstituteMilanItaly
| | - M. L. Penichet
- Division of Surgical OncologyDepartment of SurgeryDavid Geffen School of Medicine at UCLALos AngelesCAUSA
- Department of Microbiology, Immunology, and Molecular GeneticsDavid Geffen School of Medicine at UCLALos AngelesCAUSA
- Jonsson Comprehensive Cancer CenterUniversity of CaliforniaLos AngelesCAUSA
| | - F. Redegeld
- Division of PharmacologyFaculty of ScienceUtrecht Institute for Pharmaceutical SciencesUtrecht UniversityUtrechtThe Netherlands
| | - L. Saul
- Division of Genetics & Molecular MedicineFaculty of Life Sciences and MedicineSt. John's Institute of DermatologyKing's College LondonLondonUK
- Division of Cancer StudiesFaculty of Life Sciences & MedicineKing's College LondonGuy's HospitalLondonUK
| | - J. Singer
- Institute of Pathophysiology & Allergy ResearchCenter of Pathophysiology, Infectiology & ImmunologyMedical University ViennaViennaAustria
| | - J. F. Spicer
- Division of Cancer StudiesFaculty of Life Sciences & MedicineKing's College LondonGuy's HospitalLondonUK
- NIHR Biomedical Research Centre at Guy's and St. Thomas’ Hospitals and King's College LondonKing's College LondonGuy's HospitalLondonUK
| | | | - E. Spillner
- Immunological EngineeringDepartment of EngineeringAarhus UniversityAarhusDenmark
| | - M. C. Turner
- ISGlobalCentre for Research in Environmental Epidemiology (CREAL)BarcelonaSpain
- Universitat Pompeu Fabra (UPF)BarcelonaSpain
- CIBER Epidemiología y Salud Pública (CIBERESP)MadridSpain
- McLaughlin Centre for Population Health Risk AssessmentUniversity of OttawaOttawaONCanada
| | - E. Untersmayr
- Institute of Pathophysiology & Allergy ResearchCenter of Pathophysiology, Infectiology & ImmunologyMedical University ViennaViennaAustria
| | - L. Vangelista
- Department of Biomedical SciencesNazarbayev University School of MedicineAstanaKazakhstan
| | - S. N. Karagiannis
- Division of Genetics & Molecular MedicineFaculty of Life Sciences and MedicineSt. John's Institute of DermatologyKing's College LondonLondonUK
- NIHR Biomedical Research Centre at Guy's and St. Thomas’ Hospitals and King's College LondonKing's College LondonGuy's HospitalLondonUK
| |
Collapse
|
16
|
Torres MJ, Romano A, Celik G, Demoly P, Khan DA, Macy E, Park M, Blumenthal K, Aberer W, Castells M, Barbaud A, Mayorga C, Bonadonna P. Approach to the diagnosis of drug hypersensitivity reactions: similarities and differences between Europe and North America. Clin Transl Allergy 2017; 7:7. [PMID: 28293415 PMCID: PMC5347172 DOI: 10.1186/s13601-017-0144-0] [Citation(s) in RCA: 70] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2017] [Accepted: 02/22/2017] [Indexed: 12/18/2022] Open
Abstract
Drug hypersensitivity reactions (DHRs) affect an unknown proportion of the general population, and are an important public health problem due to their potential to cause life-threatening anaphylaxis and rare severe cutaneous allergic reactions. DHR evaluations are frequently needed in both ambulatory and hospital settings and have a complex diagnosis that requires a detailed clinical history and other tests that may include in vitro tests and in vivo procedures such as skin tests and drug provocation tests. Although over the years both European and U.S. experts have published statements on general procedures for evaluating DHRs, a substantial discordance in their daily management exists. In this review, we highlight both the differences and the similarities between the European and U.S. perspectives. While a general consensus exists on the importance of skin tests for evaluating DHRs, concordance between Americans and Europeans exists solely regarding their use in immediate reactions and the fact that a confirmation of a presumptive diagnosis by drug provocation tests is often the only reliable way to establish a diagnosis. Finally, great heterogeneity exists in the application of in vitro tests, which require further study to be well validated.
Collapse
Affiliation(s)
- M J Torres
- Allergy Unit, National Network ARADyAL, IBIMA-Regional University Hospital of Malaga-UMA (Pavilion C), Plaza del Hospital Civil, 29009 Malaga, Spain.,BIONAND-Andalusian Centre for Nanomedicine and Biotechnology, Malaga, Spain
| | - A Romano
- Allergy Unit, Presidio Columbus, Rome, Italy.,IRCCS Oasi Maria S.S., Troina, Italy
| | - G Celik
- Department of Chest Diseases, Division of Immunology and Allergy, Ankara University School of Medicine, Ankara, Turkey
| | - P Demoly
- Hôpital Arnaud de Villeneuve, University Hospital of Montpellier and Sorbonne Universités, UPMC Paris 06, UMR-S 1136, IPLESP, Equipe EPAR, 75013 Paris, France
| | - D A Khan
- Department of Internal Medicine, Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, TX USA
| | - E Macy
- Kaiser Permanente Health Care Program, San Diego, CA USA
| | - M Park
- Mayo Clinic College of Medicine, Division of Allergic Diseases, Mayo Clinic, Rochester, MN 55905 USA
| | - K Blumenthal
- Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA USA
| | - W Aberer
- Department of Dermatology, Medical University of Graz, Graz, Austria
| | - M Castells
- Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MSA USA
| | - A Barbaud
- Sorbonne Universities, UPMC Univ Paris 06, Dermatology and Allergology Department, Tenon Hospital (AP-HP), 4 rue de la chine, 75020 Paris, France
| | - C Mayorga
- Allergy Unit, IBIMA-Regional University Hospital of Malaga-UMA (Pavilion C), Plaza del Hospital Civil, 29009 Malaga, Spain
| | - P Bonadonna
- Allergy Unit, Azienda Ospedaliera Universitaria Intergrata of Verona, Verona, Italy
| |
Collapse
|
17
|
Ferrer F, Pont A, Letelier H, Garin O, De Blas R, Boladeras A, Garcia E, Zardoya E, Najjari D, Gonzalo P, Castells M, Mariño A, Gutierrez C, Ventura M, Rojas F, Bavestrello P, Suarez J, Picon C, Guedea F. Early Experience and Quality of Life Comparison in Prostate Cancer Brachytherapy Versus Phase I-II Stereotactic Body Radiation Therapy Trials. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
18
|
Victoria M, Tort L, Lizasoain A, García M, Castells M, Berois M, Divizia M, Leite J, Miagostovich M, Cristina J, Colina R. Norovirus molecular detection in Uruguayan sewage samples reveals a high genetic diversity and GII.4 variant replacement along time. J Appl Microbiol 2016; 120:1427-35. [DOI: 10.1111/jam.13058] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2015] [Revised: 01/06/2016] [Accepted: 01/09/2016] [Indexed: 11/28/2022]
Affiliation(s)
- M. Victoria
- Laboratory of Molecular Virology; Department of Biological Sciences; Regional Norte; CENUR Litoral Norte; Universidad de la República; Salto Uruguay
| | - L.F.L. Tort
- Laboratory of Molecular Virology; Department of Biological Sciences; Regional Norte; CENUR Litoral Norte; Universidad de la República; Salto Uruguay
| | - A. Lizasoain
- Laboratory of Molecular Virology; Department of Biological Sciences; Regional Norte; CENUR Litoral Norte; Universidad de la República; Salto Uruguay
| | - M. García
- Laboratory of Molecular Virology; Department of Biological Sciences; Regional Norte; CENUR Litoral Norte; Universidad de la República; Salto Uruguay
| | - M. Castells
- Laboratory of Molecular Virology; Department of Biological Sciences; Regional Norte; CENUR Litoral Norte; Universidad de la República; Salto Uruguay
| | - M. Berois
- Virology Section; School of Sciences; Universidad de la República; Montevideo Uruguay
| | - M. Divizia
- Laboratory of Environmental Virology; Department of Experimental Medicine and Surgery; Tor Vergata University; Rome Italy
| | - J.P.G. Leite
- Laboratory of Comparative and Environmental Virology; Oswaldo Cruz Institute; Oswaldo Cruz Foundation; Rio de Janeiro Brazil
| | - M.P. Miagostovich
- Laboratory of Comparative and Environmental Virology; Oswaldo Cruz Institute; Oswaldo Cruz Foundation; Rio de Janeiro Brazil
| | - J. Cristina
- Laboratory of Molecular Virology; Nuclear Investigation Center; School of Sciences; Universidad de la República; Montevideo Uruguay
| | - R. Colina
- Laboratory of Molecular Virology; Department of Biological Sciences; Regional Norte; CENUR Litoral Norte; Universidad de la República; Salto Uruguay
| |
Collapse
|
19
|
Foer D, Buchheit K, Lynch D, Gargiulo A, Castells M, Wickner P. Autoimmune progesterone dermatitis: clinical presentations and management. The Brigham and Women's Hospital experience. Fertil Steril 2015. [DOI: 10.1016/j.fertnstert.2015.07.302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
20
|
Affiliation(s)
- P. Giavina-Bianchi
- Clinical Immunology and Allergy Division; University of São Paulo School of Medicine; São Paulo Brazil
| | - M. V. Aun
- Clinical Immunology and Allergy Division; University of São Paulo School of Medicine; São Paulo Brazil
| | - A. A. Motta
- Clinical Immunology and Allergy Division; University of São Paulo School of Medicine; São Paulo Brazil
| | - J. Kalil
- Clinical Immunology and Allergy Division; University of São Paulo School of Medicine; São Paulo Brazil
| | - M. Castells
- Division of Rheumatology, Immunology and Allergy; Department of Medicine; Brigham and Women's Hospital; Harvard Medical School; Boston MA USA
| |
Collapse
|
21
|
Ferrer Gonzalez F, Letelier H, De Blas R, Boladeras A, Piñeiro R, Galdeano M, Najjari D, Castells M, Garcia E, Zardoya E, Suarez J, Martinez E, Gutierrez C, Pera J, Picon C, Guedea F. EP-1258: Early experience in SBRT with VMAT and flattening filterfree (FFF) beams. Phase I-II trial. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41250-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
22
|
Crestani E, Lee J, Gorman M, Castells M, Dioun Broyles AF. IgE-mediated hypersensitivity reaction and desensitization to glatiramer acetate in a pediatric patient. Pediatr Allergy Immunol 2014; 25:821-3. [PMID: 25200765 DOI: 10.1111/pai.12267] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- E Crestani
- Division of Immunology, Children's Hospital Boston, Boston, MA, USA
| | | | | | | | | |
Collapse
|
23
|
Avila MM, Pardo Y, Castells M, Ferrer F, Boladeras A, Pera J, Prada P, Guix B, de Paula B, Hernandez H, Pont A, Alonso J, Garin O, Ferrer M. Obtaining Indirect Utilities with the Sf-6d and the Porpus-U in Prostate Cancer Patients. Value Health 2014; 17:A646. [PMID: 27202321 DOI: 10.1016/j.jval.2014.08.2342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- M M Avila
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - Y Pardo
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - M Castells
- Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain
| | - F Ferrer
- Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain
| | - A Boladeras
- Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain
| | - J Pera
- Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain
| | - P Prada
- Hospital Universitario Central de Asturias, Oviedo, Spain
| | - B Guix
- Fundación IMOR, Barcelona, Spain
| | - B de Paula
- Instituto Oncológico de Guipúzcoa, Gipuzkoa, Spain
| | - H Hernandez
- Hospital Meixoeiro- Complejo CHUVI, Vigo, Spain
| | - A Pont
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - J Alonso
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - O Garin
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - M Ferrer
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| |
Collapse
|
24
|
Valent P, Escribano L, Broesby-Olsen S, Hartmann K, Grattan C, Brockow K, Niedoszytko M, Nedoszytko B, Oude Elberink JNG, Kristensen T, Butterfield JH, Triggiani M, Alvarez-Twose I, Reiter A, Sperr WR, Sotlar K, Yavuz S, Kluin-Nelemans HC, Hermine O, Radia D, van Doormaal JJ, Gotlib J, Orfao A, Siebenhaar F, Schwartz LB, Castells M, Maurer M, Horny HP, Akin C, Metcalfe DD, Arock M. Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. Allergy 2014; 69:1267-74. [PMID: 24836395 DOI: 10.1111/all.12436] [Citation(s) in RCA: 126] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/24/2014] [Indexed: 01/08/2023]
Abstract
Mastocytosis is an emerging differential diagnosis in patients with more or less specific mediator-related symptoms. In some of these patients, typical skin lesions are found and the diagnosis of mastocytosis can be established. In other cases, however, skin lesions are absent, which represents a diagnostic challenge. In the light of this unmet need, we developed a diagnostic algorithm for patients with suspected mastocytosis. In adult patients with typical lesions of mastocytosis in the skin, a bone marrow (BM) biopsy should be considered, regardless of the basal serum tryptase concentration. In adults without skin lesions who suffer from mediator-related or other typical symptoms, the basal tryptase level is an important parameter. In those with a slightly increased tryptase level, additional investigations, including a sensitive KIT mutation analysis of blood leucocytes or measurement of urinary histamine metabolites, may be helpful. In adult patients in whom (i) KIT D816V is detected and/or (ii) the basal serum tryptase level is clearly increased (>25-30 ng/ml) and/or (iii) other clinical or laboratory features suggest the presence of 'occult' mastocytosis or another haematologic neoplasm, a BM investigation is recommended. In the absence of KIT D816V and other signs or symptoms of mastocytosis or another haematopoietic disease, no BM investigation is required, but the clinical course and tryptase levels are monitored in the follow-up. In paediatric patients, a BM investigation is usually not required, even if the tryptase level is increased. Although validation is required, it can be expected that the algorithm proposed herein will facilitate the management of patients with suspected mastocytosis and help avoid unnecessary referrals and investigations.
Collapse
Affiliation(s)
- P. Valent
- Division of Haematology; Department of Internal Medicine I; Medical University of Vienna; Vienna Austria
| | - L. Escribano
- Servicio Central de Citometria; Centro de Investigacion del Cancer (IBMCC; CSIC/USAL); IBSAL and Department of Medicine; University of Salamanca; Salamanca Spain
| | - S. Broesby-Olsen
- Department of Dermatology and Allergy Centre; Odense University Hospital; Odense Denmark
| | - K. Hartmann
- Department of Dermatology; University of Cologne; Cologne Germany
| | - C. Grattan
- Norfolk and Norwich University Hospital; Norwich UK
| | - K. Brockow
- Department of Dermatology and Allergy Biederstein; Technical University of Munich; Munich Germany
| | - M. Niedoszytko
- Department of Allergology; Medical University of Gdansk; Gdansk Poland
| | - B. Nedoszytko
- Department of Dermatology; Medical University of Gdansk; Gdansk Poland
| | - J. N. G. Oude Elberink
- Department of Allergology; University Medical Center of Groningen; University of Groningen; Groningen the Netherlands
| | - T. Kristensen
- Department of Pathology; Odense University Hospital; Odense Denmark
| | | | - M. Triggiani
- Division of Allergy and Clinical Immunology; University of Salerno; Salerno Italy
| | - I. Alvarez-Twose
- Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast); Hospital Virgen del Valle; Toledo Spain
| | - A. Reiter
- III. Medizinische Klinik; Universitäts-Medizin Mannheim; Universität Heidelberg; Mannheim Germany
| | - W. R. Sperr
- Division of Haematology; Department of Internal Medicine I; Medical University of Vienna; Vienna Austria
| | - K. Sotlar
- Institute of Pathology; Ludwig-Maximilians-University; Munich Germany
| | - S. Yavuz
- Division of Haematology; Department of Internal Medicine; University of Istanbul; Istanbul Turkey
| | - H. C. Kluin-Nelemans
- Department of Haematology; University Medical Center Groningen; University of Groningen; Groningen the Netherlands
| | - O. Hermine
- Imagine Institute Université Paris Descartes, Sorbonne, Paris Cité; Centre national de référence des mastocytoses; Paris France
| | - D. Radia
- Department of Haematology; Guys and St Thomas' NHS Foundation Trust; Guys Hospital; London UK
| | - J. J. van Doormaal
- Department of Allergology; University Medical Center of Groningen; University of Groningen; Groningen the Netherlands
| | - J. Gotlib
- Stanford Cancer Institute; Stanford University School of Medicine; Stanford CA USA
| | - A. Orfao
- Servicio Central de Citometria; Centro de Investigacion del Cancer (IBMCC; CSIC/USAL); IBSAL and Department of Medicine; University of Salamanca; Salamanca Spain
| | - F. Siebenhaar
- Department of Dermatology & Allergy; Charité Universitätsmedizin Berlin; Berlin Germany
| | - L. B. Schwartz
- Division of Rheumatology, Allergy & Immunology; Department of Internal Medicine; Virginia Common-wealth University; Richmond VA USA
| | - M. Castells
- Division of Allergy and Immunology; Department of Medicine; Brigham and Women's Hospital; Harvard Medical School; Boston MA USA
| | - M. Maurer
- Department of Dermatology & Allergy; Charité Universitätsmedizin Berlin; Berlin Germany
| | - H.-P. Horny
- Institute of Pathology; Ludwig-Maximilians-University; Munich Germany
| | - C. Akin
- Division of Allergy and Immunology; Department of Medicine; Brigham and Women's Hospital; Harvard Medical School; Boston MA USA
| | - D. D. Metcalfe
- Laboratory of Allergic Diseases; NIAID; NIH; Bethesda MD USA
| | - M. Arock
- LBPA CNRS UMR8113; Ecole Normale Supérieure de Cachan; Cachan France
| |
Collapse
|
25
|
Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, Khan DA, Lang DM, Park HS, Pichler W, Sanchez-Borges M, Shiohara T, Thong BYH. International Consensus on drug allergy. Allergy 2014. [PMID: 24697291 DOI: 10.1111/all.12350)] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
When drug reactions resembling allergy occur, they are called drug hypersensitivity reactions (DHRs) before showing the evidence of either drug-specific antibodies or T cells. DHRs may be allergic or nonallergic in nature, with drug allergies being immunologically mediated DHRs. These reactions are typically unpredictable. They can be life-threatening, may require or prolong hospitalization, and may necessitate changes in subsequent therapy. Both underdiagnosis (due to under-reporting) and overdiagnosis (due to an overuse of the term ‘allergy’) are common. A definitive diagnosis of such reactions is required in order to institute adequate treatment options and proper preventive measures. Misclassification based solely on the DHR history without further testing may affect treatment options, result in adverse consequences, and lead to the use of more-expensive or less-effective drugs, in contrast to patients who had undergone a complete drug allergy workup. Several guidelines and/or consensus documents on general or specific drug class-induced DHRs are available to support the medical decision process. The use of standardized systematic approaches for the diagnosis and management of DHRs carries the potential to improve outcomes and should thus be disseminated and implemented. Consequently, the International Collaboration in Asthma, Allergy and Immunology (iCAALL), formed by the European Academy of Allergy and Clinical Immunology (EAACI), the American Academy of Allergy, Asthma and Immunology (AAAAI), the American College of Allergy, Asthma and Immunology (ACAAI), and the World Allergy Organization (WAO), has decided to issue an International CONsensus (ICON) on drug allergy. The purpose of this document is to highlight the key messages that are common to many of the existing guidelines, while critically reviewing and commenting on any differences and deficiencies of evidence, thus providing a comprehensive reference document for the diagnosis and management of DHRs.
Collapse
|
26
|
Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, Khan DA, Lang DM, Park HS, Pichler W, Sanchez-Borges M, Shiohara T, Thong BYH. International Consensus on drug allergy. Allergy 2014; 69:420-37. [PMID: 24697291 DOI: 10.1111/all.12350] [Citation(s) in RCA: 601] [Impact Index Per Article: 60.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/18/2013] [Indexed: 01/11/2023]
Abstract
When drug reactions resembling allergy occur, they are called drug hypersensitivity reactions (DHRs) before showing the evidence of either drug-specific antibodies or T cells. DHRs may be allergic or nonallergic in nature, with drug allergies being immunologically mediated DHRs. These reactions are typically unpredictable. They can be life-threatening, may require or prolong hospitalization, and may necessitate changes in subsequent therapy. Both underdiagnosis (due to under-reporting) and overdiagnosis (due to an overuse of the term ‘allergy’) are common. A definitive diagnosis of such reactions is required in order to institute adequate treatment options and proper preventive measures. Misclassification based solely on the DHR history without further testing may affect treatment options, result in adverse consequences, and lead to the use of more-expensive or less-effective drugs, in contrast to patients who had undergone a complete drug allergy workup. Several guidelines and/or consensus documents on general or specific drug class-induced DHRs are available to support the medical decision process. The use of standardized systematic approaches for the diagnosis and management of DHRs carries the potential to improve outcomes and should thus be disseminated and implemented. Consequently, the International Collaboration in Asthma, Allergy and Immunology (iCAALL), formed by the European Academy of Allergy and Clinical Immunology (EAACI), the American Academy of Allergy, Asthma and Immunology (AAAAI), the American College of Allergy, Asthma and Immunology (ACAAI), and the World Allergy Organization (WAO), has decided to issue an International CONsensus (ICON) on drug allergy. The purpose of this document is to highlight the key messages that are common to many of the existing guidelines, while critically reviewing and commenting on any differences and deficiencies of evidence, thus providing a comprehensive reference document for the diagnosis and management of DHRs.
Collapse
Affiliation(s)
- P. Demoly
- Département de Pneumologie et Addictologie; Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, France and Sorbonne Universités; Paris France
| | - N. F. Adkinson
- Division of Allergy and Clinical Immunology; The Johns Hopkins Asthma and Allergy Center; The Hopkins Bayview Medical Campus; Baltimore MD USA
| | - K. Brockow
- Department of Dermatology and Allergology Biederstein; Technische Universität München; Munich Germany
| | - M. Castells
- Division of Rheumatology, Allergy and Immunology; Department of Medicine; Brigham and Women's Hospital; Boston MA
| | - A. M. Chiriac
- Département de Pneumologie et Addictologie; Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, France and Sorbonne Universités; Paris France
| | - P. A. Greenberger
- Division of Allergy-Immunology; Northwestern University Feinberg School of Medicine; Chicago IL
| | - D. A. Khan
- Division of Allergy & Immunology; University of Texas Southwestern Medical Center; Dallas TX
| | - D. M. Lang
- Department of Allergy/Immunology; Respiratory Institute; Cleveland Clinic Foundation; Cleveland OH USA
| | - H.-S. Park
- Department of Allergy and Clinical Immunology; Ajou University School of Medicine; Suwon Korea
| | - W. Pichler
- Division of Allergology; Department of Rheumatology and Allergology/Clinical Immunology; Inselspital, University of Bern; Bern Switzerland
| | - M. Sanchez-Borges
- Allergy and Clinical Immunology Department; Centro Medico Docente La Trinidad; Caracas Venezuela
| | - T. Shiohara
- Department of Dermatology; Kyorin University School of Medicine; Tokyo Japan
| | - B. Y.-H. Thong
- Department of Rheumatology, Allergy and Immunology; Tan Tock Seng Hospital; Singapore
| |
Collapse
|
27
|
Fraile MJ, Gozalo I, Miralles J, Barrero A, Batlle M, Castells M, Garcia T, Hernández D, Ruiz C, Killick A. PS-023 Medical acceptance of sequential treatment:. Eur J Hosp Pharm 2014. [DOI: 10.1136/ejhpharm-2013-000436.374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
28
|
Giavina-Bianchi P, Caiado J, Picard M, Pur Ozyigit L, Mezzano V, Castells M, Alvarez-Cuesta E, Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D. Rapid desensitization to chemotherapy and monoclonal antibodies is effective and safe. Allergy 2013; 68:1482-3. [PMID: 24351069 DOI: 10.1111/all.12228] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- P. Giavina-Bianchi
- Clinical Immunology and Allergy Division; University of São Paulo; São Paulo Brazil
| | - J. Caiado
- Department of Immunoallergology; Hospital de Santa Maria/Centro Hospitalar Lisboa Norte; Lisbon Portugal
| | - M. Picard
- Department of Medicine; Division of Allergy and Immunology; Hôpital Maisonneuve-Rosemont; Université de Montréal; Montreal QC Canada
| | - L. Pur Ozyigit
- Department of Allergy and Immunology; American Hospital; Istanbul Turkey
| | - V. Mezzano
- Department of Clinical Immunology and Rheumatology; Pontificia Universidad Católica de Chile; Santiago Chile
| | - M. Castells
- Department of Medicine; Division of Rheumatology, Immunology and Allergy; Brigham and Women's Hospital; Harvard Medical School; Boston MA USA
| | | | | | | | - D. Angel-Pereira
- Allergy Division; Ramon y Cajal University Hospital; Madrid Spain
| |
Collapse
|
29
|
Castells M, Milhas D, Gandy C, Thibault B, Rafii A, Delord JP, Couderc B. Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation. Cell Death Dis 2013; 4:e887. [PMID: 24176845 PMCID: PMC3824693 DOI: 10.1038/cddis.2013.384] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2012] [Revised: 08/23/2013] [Accepted: 08/26/2013] [Indexed: 01/29/2023]
Abstract
Epithelial ovarian carcinoma is characterized by high frequency of recurrence (70% of patients) and carboplatin resistance acquisition. Carcinoma-associated mesenchymal stem cells (CA-MSC) have been shown to induce ovarian cancer chemoresistance through trogocytosis. Here we examined CA-MSC properties to protect ovarian cancer cells from carboplatin-induced apoptosis. Apoptosis was determined by Propidium Iodide and Annexin-V-FITC labelling and poly-ADP-ribose polymerase cleavage analysis. We showed a significant increase of inhibitory concentration 50 and a 30% decrease of carboplatin-induced apoptosis in ovarian cancer cells incubated in the presence of CA-MSC-conditioned medium (CM). A molecular analysis of apoptosis signalling pathway in response to carboplatin revealed that the presence of CA-MSC CM induced a 30% decrease of effector caspases-3 and -7 activation and proteolysis activity. CA-MSC secretions promoted Akt and X-linked inhibitor of apoptosis protein (XIAP; caspase inhibitor from inhibitor of apoptosis protein (IAP) family) phosphorylation. XIAP depletion by siRNA strategy permitted to restore apoptosis in ovarian cancer cells stimulated by CA-MSC CM. The factors secreted by CA-MSC are able to confer chemoresistance to carboplatin in ovarian cancer cells through the inhibition of effector caspases activation and apoptosis blockade. Activation of the phosphatidylinositol 3-kinase (PI3K)/Akt signalling pathway and the phosphorylation of its downstream target XIAP underlined the implication of this signalling pathway in ovarian cancer chemoresistance. This study reveals the potentialities of targeting XIAP in ovarian cancer therapy.
Collapse
Affiliation(s)
- M Castells
- 1] EA4553, Institut Claudius Regaud, Toulouse F-31052, France [2] University of Toulouse III, Toulouse F-31062, France
| | | | | | | | | | | | | |
Collapse
|
30
|
Daidone A, Gutierrez C, Martinez E, Pera J, Pino F, Gullon C, Castells M, Núñez M, del Carpio A, Boladeras A, Ferrer F. Permanent-seed-brachytherapy in prostate cancer: The Catalan-institute-of-oncology experience. Rep Pract Oncol Radiother 2013. [DOI: 10.1016/j.rpor.2013.03.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
31
|
Bavbek S, Ataman Ş, Bankova L, Castells M. Injection site reaction to adalimumab: Positive skin test and successful rapid desensitisation. Allergol Immunopathol (Madr) 2013; 41:204-6. [PMID: 23063342 DOI: 10.1016/j.aller.2012.04.006] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2012] [Revised: 04/03/2012] [Accepted: 04/09/2012] [Indexed: 11/30/2022]
MESH Headings
- Adalimumab
- Adult
- Antibodies, Monoclonal, Humanized/administration & dosage
- Antibodies, Monoclonal, Humanized/adverse effects
- Antibodies, Monoclonal, Humanized/therapeutic use
- Antirheumatic Agents/administration & dosage
- Antirheumatic Agents/adverse effects
- Antirheumatic Agents/therapeutic use
- Arthritis, Rheumatoid/drug therapy
- Desensitization, Immunologic/methods
- Diphenhydramine/therapeutic use
- Dose-Response Relationship, Drug
- Drug Eruptions/diagnosis
- Drug Eruptions/drug therapy
- Drug Eruptions/etiology
- Drug Eruptions/therapy
- Erythema/chemically induced
- Famotidine/therapeutic use
- Female
- Humans
- Injections, Subcutaneous
- Intradermal Tests
- Pruritus/chemically induced
- Skin Tests
- Time Factors
Collapse
|
32
|
Bavbek S, Aydın O, Ataman S, Cahill K, Castells M. Injection-site reaction to etanercept: role of skin test in the diagnosis of such reaction and successful desensitization. Allergy 2011; 66:1256-7. [PMID: 21507006 DOI: 10.1111/j.1398-9995.2011.02601.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Affiliation(s)
- S Bavbek
- Department of Pulmonary Diseases, Division of Allergy, Ankara University, School of Medicine, Ankara, Turkey.
| | | | | | | | | |
Collapse
|
33
|
Liu A, Fanning L, Chong H, Fernandez J, Sloane D, Sancho-Serra M, Castells M. Desensitization regimens for drug allergy: state of the art in the 21st century. Clin Exp Allergy 2011; 41:1679-89. [PMID: 21883538 DOI: 10.1111/j.1365-2222.2011.03825.x] [Citation(s) in RCA: 89] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Adverse reactions to drugs are increasingly being recognized as important contributions to disease in their own right as well as impediments to the best treatment of various conditions, including infectious, autoimmune, and neoplastic maladies. Rapid drug desensitization (RDD) is an effective mechanism for safely administering important medications while minimizing or entirely circumventing such adverse reactions in sensitized patients. We reviewed the literature on RDD in the last 10 years, including our experience from the Brigham and Women's Hospital Desensitization Program with hundreds of patients desensitized to a broad variety of drugs. RDD in our programme has been uniformly successful in patients with hypersensitivity reactions to antibiotics, chemotherapeutics, and monoclonal antibodies. Any reactions that occur during desensitization are generally much less severe than the initial hypersensitivity reaction to the drug, and patients have received the full dose of the desired medication 99.9% of the time out of (796) desensitizations. To date, there have been no fatalities. RDD is a safe and highly effective method for treating sensitized patients with the optimal pharmacologic agents. Its use should be expanded, but because patient safety is paramount, protocols must be created, reviewed, and overseen by allergist-immunologists with special training and experience in modern techniques of desensitization.
Collapse
Affiliation(s)
- A Liu
- Drug Desensitization Unit, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | | | | | | | | | | | | |
Collapse
|
34
|
Cernadas JR, Brockow K, Romano A, Aberer W, Torres MJ, Bircher A, Campi P, Sanz ML, Castells M, Demoly P, Pichler WJ. General considerations on rapid desensitization for drug hypersensitivity - a consensus statement. Allergy 2010; 65:1357-66. [PMID: 20716314 DOI: 10.1111/j.1398-9995.2010.02441.x] [Citation(s) in RCA: 236] [Impact Index Per Article: 16.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Drug hypersensitivity reactions can occur with most drugs, are unpredictable, may affect any organ or system, and range widely in clinical severity from mild pruritus to anaphylaxis. In most cases, the suspected drug is avoided in the future. However, for certain patients, the particular drug may be essential for optimal therapy. Under these circumstances, desensitization may be performed. Drug desensitization is defined as the induction of a temporary state of tolerance of a compound responsible for a hypersensitivity reaction. It is performed by administering increasing doses of the medication concerned over a short period of time (from several hours to a few days) until the total cumulative therapeutic dose is achieved and tolerated. It is a high-risk procedure used only in patients in whom alternatives are less effective or not available after a positive risk/benefit analysis. Desensitization protocols have been developed and are used in patients with allergic reactions to antibiotics (mainly penicillin), insulins, sulfonamides, chemotherapeutic and biologic agents, and many other drugs. Desensitization is mainly performed in IgE-mediated reactions, but also in reactions where drug-specific IgE have not been demonstrated. Desensitization induces a temporary tolerant state, which can only be maintained by continuous administration of the medication. Thus, for treatments like chemotherapy, which have an average interval of 4 weeks between cycles, the procedure must be repeated for every new course. In this paper, some background information on rapid desensitization procedures is provided. We define the drugs and drug reactions indicated for such procedures, describe the possible mechanism of action, and discuss the indications and contraindications. The data should serve as background information for a database (accessible via the EAACI-homepage) with standardized protocols for rapid desensitization for antibiotics, chemotherapeutic agents, monoclonal antibodies/fusion proteins, and other drugs.
Collapse
Affiliation(s)
- J R Cernadas
- Department of Allergy and Clinical Immunology, Medical University, H. S. João, Porto, Portugal.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Rachid R, Castells M, Cunningham-Rundles C, Bonilla F. Association of Anti-Iga Antibodies with Adverse Reactions with Gammaglobulin Infusion. J Allergy Clin Immunol 2010. [DOI: 10.1016/j.jaci.2009.12.551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
36
|
|
37
|
Castells M, Ramos A, Sanchis V, Marín S. Reduction of fumonisin B1in extruded corn breakfast cereals with salt, malt and sugar in their formulation. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2009; 26:512-7. [DOI: 10.1080/02652030802562896] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
38
|
DuBuske L, Castells M, Holdich T. Significant Reduction In Combined Symptom And Medication Score Compared With Placebo Following MPL-Adjuvanted uSCIT In Patients With Seasonal Grass Pollen Allergy. J Allergy Clin Immunol 2009. [DOI: 10.1016/j.jaci.2008.12.827] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
39
|
|
40
|
Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K, Castells M, Sperr WR, Kluin-Nelemans HC, Hamdy NAT, Lortholary O, Robyn J, van Doormaal J, Sotlar K, Hauswirth AW, Arock M, Hermine O, Hellmann A, Triggiani M, Niedoszytko M, Schwartz LB, Orfao A, Horny HP, Metcalfe DD. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37:435-53. [PMID: 17537151 DOI: 10.1111/j.1365-2362.2007.01807.x] [Citation(s) in RCA: 515] [Impact Index Per Article: 30.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Although a classification for mastocytosis and diagnostic criteria are available, there remains a need to define standards for the application of diagnostic tests, clinical evaluations, and treatment responses. To address these demands, leading experts discussed current issues and standards in mastocytosis in a Working Conference. The present article provides the resulting outcome with consensus statements, which focus on the appropriate application of clinical and laboratory tests, patient selection for interventional therapy, and the selection of appropriate drugs. In addition, treatment response criteria for the various clinical conditions, disease-specific symptoms, and specific pathologies are provided. Resulting recommendations and algorithms should greatly facilitate the management of patients with mastocytosis in clinical practice, selection of patients for therapies, and the conduct of clinical trials.
Collapse
Affiliation(s)
- P Valent
- Department of Internal Medicine I, Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna, Austria.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
González de Olano D, de la Hoz Caballer M, López RN, Muñoz LS, Agustín MC, Dieguez M, Castells M, Escribano Mora L. Prevalence of Allergy and Anaphylaxis in 210 Patients with Mastocytosis. A Study From The Spanish Network on Mastocytosis (REMA). J Allergy Clin Immunol 2007. [DOI: 10.1016/j.jaci.2006.11.128] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
42
|
Abstract
Extrusion cooking is one of the fastest growing food-processing operations in recent years due to several advantages over traditional methods. Apart from its main goal of improving the quality of intermediate and final processed products, it may incidentally also improve safety because of the potential to reduce mycotoxin levels in cereals. This review is focused on extrusion cooking and aims to give a general overview of its impact in reducing mycotoxin levels in cereals. Extrusion cooking generally decreases the mycotoxins levels at rates depending on different factors such as the type of extruder, the type of screw, the die configuration, the initial mycotoxin concentration, the barrel temperature, the screw speed, the moisture content of the raw material and the use of additives. Reductions of 100, 95 and 83% for fumonisins, aflatoxins and zearalenone, respectively, have been reported during extrusion cooking of cereals, while lower reductions were observed for deoxynivalenol, ochratoxin A and moniliformin, where maximum reductions did not exceed 55, 40 and 30%, respectively.
Collapse
Affiliation(s)
- M Castells
- Food Technology Department, Lleida University, Lleida, Spain
| | | | | | | |
Collapse
|
43
|
Feldweg A, Price K, Matulonis U, Castells M. Successful desensitization to paclitaxel (Taxol®) in ten patients using a standardized protocol. J Allergy Clin Immunol 2003. [DOI: 10.1016/s0091-6749(03)80573-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
44
|
Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol 2002; 81:677-90. [PMID: 12483363 DOI: 10.1007/s00277-002-0575-z] [Citation(s) in RCA: 135] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2002] [Accepted: 10/12/2002] [Indexed: 10/27/2022]
Abstract
Mastocytosis consists of a group of disorders characterized by a pathologic increase in mast cells in tissues including skin, bone marrow, liver, spleen, and lymph nodes. Mastocytosis is a rare disease. Because of this, general practitioners have limited exposure to its clinical manifestations, diagnosis, classification, and management. Diagnosis of mastocytosis is suspected on clinical grounds and is established by histopathologic examination of involved tissues such as skin and bone marrow. The most common clinical sign of mastocytosis is the presence of typical skin lesions of urticaria pigmentosa. Most patients experience symptoms related to mast cell mediator release, and prevention of the effects of these mediators on tissues constitutes the major therapeutic goal in the management of mastocytosis. Despite recent advances in knowledge about the pathophysiology, diagnosis, and classification of mastocytosis, a curative treatment for mastocytosis does not now exist. Management of patients within all categories of mastocytosis includes: (1) a careful counseling of patients (parents in pediatric cases) and care providers, (2) avoidance of factors triggering acute mediator release, (3) treatment of acute mast cell mediator release, (4) treatment of chronic mast cell mediator release, and if indicated (5) an attempt to treat organ infiltration by mast cells. The goal of this manuscript is to provide an overview of the mediators produced and released by mast cells, the diagnostic criteria for the different variants of mastocytosis, and the treatment options currently available.
Collapse
Affiliation(s)
- L Escribano
- Hospital Ramón y Cajal, Unidad de Mastocitosis, Carretera de Colmenar Km 9.1, Madrid 28034, Spain.
| | | | | | | | | |
Collapse
|
45
|
Affiliation(s)
- A Aguilar
- Department of Urology, Hospital San Lorenc Viladecans, Barcelona, Spain
| | | | | | | |
Collapse
|
46
|
Castells M. A rejoinder to Abell and Reyniers' 'failure of social theory'. Br J Sociol 2001; 52:541-546. [PMID: 11578008 DOI: 10.1080/00071310120071179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Affiliation(s)
- M Castells
- Department of Sociology, University of California, Berkeley, USA
| |
Collapse
|
47
|
Espaulella J, Guyer H, Diaz-Escriu F, Mellado-Navas JA, Castells M, Pladevall M. Nutritional supplementation of elderly hip fracture patients. A randomized, double-blind, placebo-controlled trial. Age Ageing 2000; 29:425-31. [PMID: 11108415 DOI: 10.1093/ageing/29.5.425] [Citation(s) in RCA: 93] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND undernourishment is common in elderly hip fracture patients and has been linked to poorer recovery and increased post-operative complications. OBJECTIVE to determine whether a nutritional supplement may (i) help elderly patients return to pre-fracture functional levels 6 months post-fracture and (ii) decrease fracture-related complications and mortality. DESIGN a double-blind, randomized, placebo-controlled clinical trial. SETTING a county hospital near Barcelona. SUBJECTS 171 patients, aged 70 and older, hospitalized for hip fracture between July 1994 and July 1996. METHODS we randomized patients to intervention (n = 85) or control (n = 86) group. Patients received a nutritional supplement containing 20 g of protein and 800 mg of calcium or placebo for 60 days. We determined functional levels by the Barthel index, the mobility index and by the use of walking aids. We performed assessments during hospitalization and at 2 and 6 months post-fracture. FINDINGS the two groups were comparable at study entry. We observed no differences in return to functional status 6 months post-fracture (61% intervention group vs 55% in control group) nor in fracture-related mortality (13% in intervention group vs 10% in control group). The intervention group suffered fewer in-hospital [odds ratio 1.88 (95% CI 1.01 - 3.53), P = 0.05] and total complications [odds ratio 1.94 (95% CI 1.02-3.7), P = 0.04] than the control group. CONCLUSION based on our results, we cannot recommend routine nutritional supplementation of all elderly hip fracture patients. While nutritional supplementation may be useful in decreasing complications, this reduction does not result in improvement in functional recovery and nor does it decrease fracture-related mortality. Selected patients may, however, benefit from nutritional supplementation.
Collapse
Affiliation(s)
- J Espaulella
- Department of Geriatrics, Hospital de la Santa Creu de Vic, Barcelona, Spain
| | | | | | | | | | | |
Collapse
|
48
|
|
49
|
|
50
|
Abstract
Mast cells are important effector cells providing granule and membrane mediators as well as cytokines in allergic and inflammatory diseases. The study of surface molecules such as immunoglobulin receptors and adhesion molecules has greatly expanded the functional implications of mast cells. An active role for mast cells in antigen presentation to T cells has recently been shown, and direct interaction between mast cells and B cells providing signals for specific IgE production has been demonstrated. Functional receptors other than the high affinity IgE (Fc epsilon RI) have been implicated in the anaphylactic response of IgE-deficient mice, suggesting that IgG receptors present in mast cells may be involved in immediate hypersensitivity reactions. Although metachromatic mast cells are easily recognized in peripheral tissues, little is known about the phenotype of mast cell precursors, their fate from the bone marrow to the tissues, migration and homing processes, and factors and adhesion molecules that affect those processes. This review will describe the most recent studies in mouse and human mast cell biology and ontogeny.
Collapse
Affiliation(s)
- M Castells
- Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA
| |
Collapse
|